Autoimmune haemolytic anaemia and neuropathy with IgA osteosclerotic myeloma: a case report

Pathology ◽  
2017 ◽  
Vol 49 (6) ◽  
pp. 646-647 ◽  
Author(s):  
Philip J. Crispin ◽  
Poh Lin Cheah
Keyword(s):  
Case Report ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia ◽  
Osteosclerotic Myeloma

Myasthenia gravis with thymoma and autoimmune haemolytic anaemia. A case report

2003 ◽  
Vol 24 (1) ◽  
pp. 34-36 ◽  
Author(s):  
N. Tuncer Elmaci ◽  
S. Ratip ◽  
D. ?nce-G�nal ◽  
T. Tanrida?
Keyword(s):  
Case Report ◽  
Myasthenia Gravis ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia

Case report: A patient with primary biliary cirrhosis and autoimmune haemolytic anaemia

1996 ◽  
Vol 11 (5) ◽  
pp. 439-442 ◽  
Author(s):  
ERIC M YOSHIDA ◽  
STEPHEN H NANTEL ◽  
DAVID A OWEN ◽  
PAUL F GALBRAITH ◽  
BAKUL I DALAL ◽  
...  
Keyword(s):  
Case Report ◽  
Primary Biliary Cirrhosis ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia ◽  
Biliary Cirrhosis

An elderly man presented with autoimmune haemolytic anaemia- a consequence of severe corona virus disease 19 (COVID-19)

2021 ◽  
pp. 57-59
Author(s):  
Md Nazmul Hasan ◽  
Chowdhury Adnan Sami ◽  
Md Rasul Amin ◽  
Abed Hussain Khan ◽  
Sunil Kumar Biswas
Keyword(s):  
Case Report ◽  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Haemolytic Anaemia ◽  
Lymphoproliferative Disorder ◽  
Virus Disease ◽  
Autoimmune Haemolytic Anaemia ◽  
Corona Virus ◽  
Increased Risk

Autoimmune hemolytic anaemia (AIHA) can be caused by many diseases like connective tissue disease, lymphoproliferative disorder, certain infections and various medications. The coronavirus disease 19(COVID-19) can cause an increased risk of thrombosis. But, the association of AIHA with COVID-19 is not well understood. Here, in this case report a 45-year-old man who presented with fever, cough, anaemia and splenomegaly. On further investigation, he was confirmed as severe COVID-19 case with AIHA. Subsequently he was managed with prednisolone with good results. BSMMU J 2021; 14 (COVID -19 Supplement): 57-59

scholarly journals Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report

2021 ◽  
pp. 1289-1294
Author(s):  
Anna Carbó-Bagué ◽  
Roser Fort-Culillas ◽  
Helena Pla-Juher ◽  
Jordi Rubió-Casadevall
Keyword(s):  
Adverse Event ◽  
Case Report ◽  
Haemolytic Anaemia ◽  
Checkpoint Inhibitors ◽  
Immune Surveillance ◽  
Subsequent Treatment ◽  
Autoimmune Haemolytic Anaemia ◽  
Adjuvant Setting ◽  
First Case ◽  
Inhibitor Treatment

Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case published in the literature with the change of immunotherapy treatment to anti-CTLA4.

Sign in / Sign up

Export Citation Format

Share Document